A randomised trial of enteric-coated nutrient pellets to stimulate gastrointestinal peptide release and lower glycaemia in type 2 diabetes

Diabetologia

Volumn 56, Issue 6, 2013, Pages 1236-1242

  Ma, J ^a,b,e   Checklin, H L ^a,b   Wishart, J M ^a,b   Stevens, J E ^a,b   Jones, K L ^a,b   Horowitz, M ^a,b   Meyer, J H ^c   Rayner, C K ^a,b,d  

^a Discipline of Medicine   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c Meyer Nutriceuticals   (United States)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Glucagon like peptide 1; Incretin; Lauric acid

Indexed keywords

GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; LAURIC ACID; PLACEBO;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ENTERIC COATED TABLET; FEMALE; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; INSULIN BLOOD LEVEL; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AREA UNDER CURVE; BLOOD GLUCOSE; COLON; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; ILEUM; INSULIN; LAURIC ACIDS; MALE; METFORMIN; MIDDLE AGED; TABLETS, ENTERIC-COATED; TIME FACTORS;

EID: 84877751318     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2876-2     Document Type: Article

References (40)

1. UKPDS Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 352:837-853
2. Ray KK, Seshasai SR, Wijesuriya S et al (2009) Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 373:1765-1772
3. Turnbull FM, Abraira C, Anderson RJ et al (2009) Intensive glucose control and macrovascular outcomes in type 2 diabetes. Diabetologia 52:2288-2298
4. Monnier L, Colette C, Dunseath GJ, Owens DR (2007) The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes. Diabetes Care 30:263-269
5. Riddle M, Umpierrez G, DiGenio A, Zhou R, Rosenstock J (2011) Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes. Diabetes Care 34:2508-2514
6. Rayner CK, Samsom M, Jones KL, Horowitz M (2001) Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 24:371-381
7. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y (1964) Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 24:1076-1082
8. McIntyre N, Holdsworth CD, Turner DS (1964) New interpretation of oral glucose tolerance. Lancet 41:20-21
9. Ma J, Pilichiewicz AN, Feinle-Bisset C et al (2012) Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes. Diabet Med 29:604-608
10. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993) Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91:301-307
11. Hare KJ, Knop FK, Asmar M et al (2009) Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J Clin Endocrinol Metab 94:4679-4687
12. Deane AM, Nguyen NQ, Stevens JE et al (2010) Endogenous glucagon-like peptide-1 slows gastric emptying in healthy subjects, attenuating postprandial glycemia. J Clin Endocrinol Metab 95:215-221
13. Drucker DJ, Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705
14. Gentilcore D, Chaikomin R, Jones KL et al (2006) Effects of fat on gastric emptying of, and the glycemic, insulin and incretin responses to, a carbohydrate meal in type 2 diabetes. J Clin Endocrinol Metab 91:2062-2067
15. Ma J, Stevens JE, Cukier K et al (2009) Effects of a protein preload on gastric emptying, glycemia, and gut hormones after a carbohydrate meal in diet-controlled type 2 diabetes. Diabetes Care 32:1600-1602
16. Lin HC, Doty JE, Reedy TJ, Meyer JH (1989) Inhibition of gastric emptying by glucose depends on length of intestine exposed to nutrient. Am J Physiol 256:G404-G411
17. Lin HC, Doty JE, Reedy TJ, Meyer JH (1990) Inhibition of gastric emptying by sodium oleate depends on length of intestine exposed to nutrient. Am J Physiol 259:G1031-G1036
18. Little TJ, Doran S, Meyer JH et al (2006) The release of GLP-1 and ghrelin, but not GIP and CCK, by glucose is dependent upon the length of small intestine exposed. Am J Physiol Endocrinol Metab 291:E647-E655
19. Baggio LL, Drucker DJ (2007) Biology of incretins: GLP-1 and GIP. Gastroenterology 132:2131-2157
20. Read NW, McFarlane A, Kinsman RI et al (1984) Effect of infusion of nutrient solutions into the ileum on gastrointestinal transit and plasma levels of neurotensin and enteroglucagon. Gastroenterology 86:274-280
21. Feltrin KL, Little TJ, Meyer JH et al (2004) Effects of intraduodenal fatty acids on appetite, antropyloroduodenal motility, and plasma CCK and GLP-1 in humans vary with their chain length. Am J Physiol Regul Integr Comp Physiol 287:R524-R533
22. Feltrin KL, Patterson M, Ghatei MA et al (2006) Effect of fatty acid chain length on suppression of ghrelin and stimulation of PYY, GLP-2 and PP secretion in healthy men. Peptides 27:1638-1643
23. Little TJ, Feltrin KL, Horowitz M et al (2005) Dose-related effects of lauric acid on antropyloroduodenal motility, gastrointestinal hormone release, appetite, and energy intake in healthy men. Am J Physiol Regul Integr Comp Physiol 289:R1090-R1098
24. Kinget R, Kalala W, Vervoort L, van den Mooter G (1998) Colonic drug targeting. J Drug Target 6:129-149
25. Meyer JH, Lake R, Elashoff JD (2001) Postcibal gastric emptying of pancreatin pellets: effects of dose and meal oil. Dig Dis Sci 46:1846-1852
26. Ewing DJ, Clarke BF (1982) Diagnosis and management of diabetic autonomic neuropathy. Br Med J 285:916-918
27. Horowitz M, Maddox AF, Wishart JM, Harding PE, Chatterton BE, Shearman DJ (1991) Relationships between oesophageal transit and solid and liquid gastric emptying in diabetes mellitus. Eur J Nucl Med 18:229-234
28. Wishart J, Morris HA, Horowitz M (1992) Radioimmunoassay of gastric inhibitory polypeptide in plasma. Clin Chem 38:2156-2157
29. Nauck MA, Niedereichholz U, Ettler R et al (1997) Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273:E981-E988
30. Little TJ, Pilichiewicz AN, Russo A et al (2006) Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses. J Clin Endocrinol Metab 91:1916-1923
31. Lund A, Vilsboll T, Bagger JI, Holst JJ, Knop FK (2011) The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. Am J Physiol Endocrinol Metab 300:E1038-E1046
32. Vahl TP, Tauchi M, Durler TS et al (2007) Glucagon-like peptide-1 (GLP-1) receptors expressed on nerve terminals in the portal vein mediate the effects of endogenous GLP-1 on glucose tolerance in rats. Endocrinology 148:4965-4973
33. Nishizawa M, Moore MC, Shiota M et al (2003) Effect of intraportal glucagon-like peptide-1 on glucose metabolism in conscious dogs. Am J Physiol Endocrinol Metab 284:E1027-E1036
34. Ionut V, Hucking K, Liberty IF, Bergman RN (2005) Synergistic effect of portal glucose and glucagon-like peptide-1 to lower systemic glucose and stimulate counter-regulatory hormones. Diabetologia 48:967-975
35. Johnson KM, Edgerton DS, Rodewald T et al (2007) Intraportal GLP-1 infusion increases nonhepatic glucose utilization without changing pancreatic hormone levels. Am J Physiol Endocrinol Metab 293:E1085-E1091
36. Niijima A (1989) Neural mechanisms in the control of blood glucose concentration. J Nutr 119:833-840
37. Holst JJ, Deacon CF (2005) Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors. Diabetologia 48:612-615
38. Waget A, Cabou C, Masseboeuf M et al (2011) Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 152:3018-3029
39. Nelson DW, Sharp JW, Brownfield MS, Raybould HE, Ney DM (2007) Localization and activation of glucagon-like peptide-2 receptors on vagal afferents in the rat. Endocrinology 148:1954-1962
40. Mannucci E, Tesi F, Bardini G et al (2004) Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. Diabetes Nutr Metab 17:336-342